An official website of the United States government
Home
Name
Dasatinib
Alternate Names
Sprycel
Abbreviations
None
Category
Chemotherapy
Subcategory
Cytostatic agent--multi-target kinase inhibitor
NSC Number
732517
Primary Site
breast
CLL
CML
Ph+ ALL
prostate
Histology
None
Remarks
FDA approved 2006; orphan drug for Ph+ ALL; Phase II breast, prostate, CLL Bristol-Myers Squibb. Used when Gleevec fails for CML
November 9, 2017: FDA granted regular approval to dasatinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
November 9, 2017: FDA granted regular approval to dasatinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
Coding
This drug should be coded
